Pfizer Inc PFE

$28.00 +0.50 (1.82%)

Valuation

Market cap
156,228,064,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.11
Forward PE
9.34
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
30,161,088
Avg volume
35,833,648
Day's range
$27.55 – $28.17
Shares out
5,699,674,000
Stochastic %K
21%
Beta
0.32
Analysts
Sell
Price target
$28.95

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 7, 7:57 PM
$GLSI https://www.pfizer.com/news/press-release/press-release-detail/pfizers-tukysa-regimen-receives-fda-approval-front-line you know $PFE is looking at $SLS
0 replies
notreload_ai Oct 7, 7:49 PM
$PFE Tukysa is now FDA-approved as a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer, delaying progression. https://notreload.xyz/xy/fda-approves-pfizer-tukysa-for-her2-breast-cancer/
0 replies
TheSaint229 Oct 7, 7:24 PM
$SPY I think pharma stock going to do good plagues fear if they keep pushing that shit on the news media. Mrna is going hit ath imo $MRNA $PFE
0 replies
Makingmillions192 Oct 7, 6:49 PM
$PFE Lexaria enters into MTA with PegBio to test DHT for GLP1... #glp1 #biotech https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-enters-a-material-transfer-agreement-with-pegbio-1206856
0 replies
sam92 Oct 7, 6:31 PM
$PFE Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancer
0 replies
flychicken1991 Oct 7, 5:26 PM
$PFE FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer. Impact: Positive (88%). The expanded Tukysa indication puts upward pressure on PFE's valuation by increasing potential drug revenue and removing regulatory uncertainty for this maintenance use; the size of the incremental earnings contribution is unverified. Source and what to watch next: https://nimpact.tech/newsimpact/news/5146308825a5d74a/pfe-fda-approves-tucatinib-with-trastuzumab-and-pertuzumab-for-the-maint?utm_source=stocktwits&utm_medium=story_url
0 replies
peloswing Oct 7, 5:25 PM
$PFE still on the road to $30 and beyond WINS FDA APPROVAL FOR TUKYSA + TRASTUZUMAB/PERTUZUMAB AS MAINTENANCE TREATMENT IN HER2+ METASTATIC BREAST CANCER
1 replies
focafoca99 Oct 7, 5:15 PM
$PFE gets FDA approval for TUKYSA as a front-line maintenance therapy for HER2+ metastatic breast cancer. https://www.rapidticker.com/news/pfe-pfizers-tukysa-regimen-receives-fda-ddf212
0 replies